<DOC>
	<DOCNO>NCT01176500</DOCNO>
	<brief_summary>Background : - Fluciclatide small cyclic peptide contain RGD tri-peptide , preferentially bind high affinity alpha ( v ) beta ( 3 ) integrins , up-regulated may regulate angiogenesis . - [ 18F ] Fluciclatide new radiopharmaceutical develop PET image - Changes [ 18F ] fluciclatide uptake evaluated treatment patient target antiangiogenic drug Objectives : Primary - To determine tumor uptake retention [ 18F ] fluciclatide 1 cycle treatment target anti-angiogenic therapy - Secondary - To assess safety multiple intravenous ( IV ) administration Fluciclatide [ 18F ] Injection subject solid tumor - To obtain preliminary data relationship [ 18F ] fluciclatide pharmacodynamic marker standard care image marker clinical response ( e.g . contrast-enhanced ( CE ) static compute tomography ( CT ) , bone scintigraphy , FDG-PET ) , obtain part routine clinical follow-up specify refer protocol , well optional imaging perform Eligibility : - Patients great equal 18 year , document malignancy , solid tumor great equal 1 cm outside liver , schedule enroll NCI therapy protocol use one anti-angiogenic agent describe full protocol - Platelet count great 75,000 x 10 ( 6 ) /L , hemoglobin great 9g/dL , prothrombin time ( PT ) aPTT less 2 time normal limit . - The subject receive targeted anti-angiogenic agent within 60 day prior pre-treatment ( baseline ) [ 18F ] fluciclatide administration Design : This study intend obtain preliminary data uptake retention [ 18F ] fluciclatide anti-angiogenic therapy . This enable optimization image protocol , identification relevant imaging parameter , allow calculation number patient required power large study assess utility PET image [ 18F ] fluciclatide pharmacodynamic biomarker context target anti-angiogenic therapy . We expect enroll 30 evaluable patient single center study . Subjects undergo least two [ 18F ] fluciclatide PET/CT image study , one pre-therapy one follow completion 1 cycle chemotherapy . An optional early post-therapy ( 2-7 day post therapy commencement ) [ 18F ] fluciclatide PET/CT may perform . The magnitude [ 18F ] fluciclatide uptake pre- post- treatment PET/CT study evaluate determine measureable difference uptake . Data subject 's refer therapy protocol review one year . An optional DCE-MRI scan target lesion may also perform .</brief_summary>
	<brief_title>A Pilot , Open-label Study 18F-Fluciclatide PET/CT Imaging Evaluation Anti-angiogenic Therapy Solid Tumors</brief_title>
	<detailed_description>Background : - Fluciclatide small cyclic peptide contain RGD tri-peptide , preferentially bind high affinity alpha ( v ) beta ( 3 ) integrins , up-regulated may regulate angiogenesis . - [ 18F ] Fluciclatide new radiopharmaceutical develop PET image - Changes [ 18F ] fluciclatide uptake evaluated treatment patient target antiangiogenic drug Objectives : Primary - To determine tumor uptake retention [ 18F ] fluciclatide 1 cycle treatment target anti-angiogenic therapy - Secondary - To assess safety multiple intravenous ( IV ) administration Fluciclatide [ 18F ] Injection subject solid tumor - To obtain preliminary data relationship [ 18F ] fluciclatide pharmacodynamic marker standard care image marker clinical response ( e.g . contrast-enhanced ( CE ) static compute tomography ( CT ) , bone scintigraphy , FDG-PET ) , obtain part routine clinical follow-up specify refer protocol , well optional imaging perform Eligibility : - Patients great equal 18 year , document malignancy , solid tumor great equal 1 cm outside liver , schedule enroll NCI therapy protocol use one anti-angiogenic agent describe full protocol - Platelet count great 150,000 x 10 ( 6 ) /L , hemoglobin great 9g/dL , prothrombin time ( PT ) aPTT less 2 time normal limit . - The subject receive targeted anti-angiogenic agent within 60 day prior pre-treatment ( baseline ) [ 18F ] fluciclatide administration Design : This study intend obtain preliminary data uptake retention [ 18F ] fluciclatide anti-angiogenic therapy . This enable optimization image protocol , identification relevant imaging parameter , allow calculation number patient required power large study assess utility PET image [ 18F ] fluciclatide pharmacodynamic biomarker context target anti-angiogenic therapy . We expect enroll 30 evaluable patient single center study . Subjects undergo least two [ 18F ] fluciclatide PET/CT image study , one pre-therapy one follow completion 1 cycle chemotherapy . An optional early post-therapy ( 2-7 day post therapy commencement ) [ 18F ] fluciclatide PET/CT may perform . The magnitude [ 18F ] fluciclatide uptake pre- post- treatment PET/CT study evaluate determine measureable difference uptake . Data subject 's refer therapy protocol review one year . An optional DCE-MRI scan target lesion may also perform .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : Adult subject ( great equal to18 year old ) , documented malignancy , least one solid tumor great equal 1 cm diameter ( within liver ) , schedule enroll NCI therapy protocol use one antiangiogenic therapy agent ( Vandetanib , Cediranib Bevacizumab ) The subject platelet count 150,000 x 10 ( 6 ) /L , hemoglobin value great 9 g/dL , PT aPTT less 2 time normal limit . The subject clinically acceptable medical history , physical examination vital sign finding screen period ( less 4 week administration Fluciclatide ( 18F ) Injection ) ; i.e . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . The subject open surgical wound close proximity target lesion ( ) within 10 day prior study entry . The subject biopsy target lesion within 7 day PET/CT imaging . The subject radiation therapy region target lesion . Enrolling follow NCI antiangiogenic therapy protocol : 08C0020 09C0192 07C0058 09C0019 EXCLUSION CRITERIA : The subject pregnant lactating . The subject treat dos heparin warfarin result elevation PT aPTT great 2 time normal . The subject receive antiangiogenic agent ( e.g . bevacizumab , sorafenib , sunitinib ) within 60 day prior pretreatment ( baseline ) [ 18F ] fluciclatide PET image . This stipulation apply baseline [ 18F ] fluciclatide PET imaging . The subject receive another investigational medicinal product ( IMP ) within 24 hour schedule receive another IMP within 24 hour Fluciclatide ( 18F ) Injection . The subject contraindication study procedure , product use constituent ( e.g . severe claustrophobia unrelieved oral anxiolytic ) . The subject unable lie still 75 minute . The subject known history hyper hypocoagulation syndrome result prolongation bleed parameter . Such coagulopathies include limited Von Willebrand disease , Protein C deficiency , Protein S deficiency , Hemophilia A/B/C , FactorV Leiden , BernardSoulier syndrome . The subject undergone surgical procedure target lesion within 28 day prior baseline [ 18F ] fluciclatide administration OR schedule undergo surgical procedure baseline post 1cycle [ 18F ] fluciclatide PET/CT . The subject bone metastasis ADDITIONAL INCLUSION CRITERIA FOR SUBJECTS UNDERGOING OPTIONAL MR : Serum creatinine within 2 week prior MRI le equal 1.8mg/dl estimate glomerular filtration rate ( eGFR ) must great 30 ml/min/1.73m ( 2 ) . ADDITIONAL EXCLUSION CRITERIA FOR SUBJECTS UNDERGOING OPTIONAL MR : The subject know allergy gadolinium The subject contraindication MRI : Subjects must weigh less 136 kg ( weight limit scanner table ) . Subjects pacemaker , cerebral aneurysm clip , shrapnel injury , implant electronic device metal compatible MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 18, 2011</verification_date>
	<keyword>PET Imaging</keyword>
	<keyword>( 18F ) Fluciclatide</keyword>
	<keyword>Anti-Angiogenic Therapies</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>